SCHEMBL5565626

SCHEMBL5565626

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(OC4CCNCC4)cc3)cc2)ccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 8/20 0.63
EPHX2 P34913 5/20 0.63
CSF1R P07333 3/20 0.60
FLT3 P36888 3/20 0.60
DDR2 Q16832 2/20 0.58
MAPK14 Q16539 5/20 0.58
KDR P35968 5/20 0.58
SRC P12931 3/20 0.58
HIPK4 Q8NE63 3/20 0.58
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
MAPK13 O15264 2/20 0.58
MAP4K4 O95819 2/20 0.58
ABL1 P00519 2/20 0.58
LCK P06239 2/20 0.58
FYN P06241 2/20 0.58
LYN P07948 2/20 0.58
RET P07949 2/20 0.58
RPS6KB1 P23443 2/20 0.58
EPHA2 P29317 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569557 0.94 RAF1 (0.61) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL5569252 0.89 RAF1 (0.59) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL14471165 0.89 DDR2 (0.58) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL5568423 0.87 RAF1 (0.66) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL5568235 0.87 DDR2 (0.56) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL5565332 0.86 DDR2 (0.58) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL3110977 0.85 CSF1R (0.56) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL257980 0.85 RAF1 (0.82) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL14453617 0.85 DDR2 (0.81) RAF1EPHX2CSF1RFLT3DDR2
SCHEMBL5569800 0.84 KDR (0.59) RAF1EPHX2CSF1RFLT3DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A 2007-07-19 JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP disclosed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS RAF1 2/4885EPHX2 1462/4885CSF1R 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.